Barclays Upgrades Celldex to Overweight, Raises Price Target to $45 Barclays boosts Celldex Therapeutics on strong drug outlook; higher success odds and sales expectations. Credit: Celldex Therapeutics Subscribe now Already have an account? Sign in.
